SOFTIFLOX 5 MG FLAVOURED CHEWABLE TABLETS FOR CATS

Riik: Iirimaa

keel: inglise

Allikas: HPRA (Health Products Regulatory Authority)

Osta kohe

Toote omadused Toote omadused (SPC)
12-06-2017

Toimeaine:

MARBOFLOXACIN

Saadav alates:

Norbrook Laboratories Limited

ATC kood:

QJ01MA93

INN (Rahvusvaheline Nimetus):

MARBOFLOXACIN

Annus:

5 mg/tablet

Ravimvorm:

Tablets

Retsepti tüüp:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapeutiline rühm:

Canine, Feline

Terapeutiline ala:

marbofloxacin

Näidustused:

Antibacterial

Volitamisolek:

Authorised

Loa andmise kuupäev:

2013-03-22

Toote omadused

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Softiflox 5 mg flavoured chewable tablets for cats and dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Chewable Tablet contains:
Active Substance:
Marbofloxacin
5.0 mg
Excipients :
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Chewable Tablet.
Light brown round convex tablet with breakline.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats and dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs:
Indicated for
the treatment
of
skin and soft
tissue infections (skinfold pyoderma,
impetigo,
folliculitis,
furunculosis,
cellulitis)
caused by susceptible strains of
organisms,
urinary tract
infections associated or
not
with
prostatitis caused by susceptible strains of
organisms and respiratory infections,
caused by susceptible strains of
organisms.
In cats:
Indicated for
the treatment
of
skin and soft
tissue infections (wounds,
abscesses phlegmons)
and upper
respiratory tract infections caused by susceptible strains of
organisms.
4.3 CONTRAINDICATIONS
Do not
use in animals with known hypersensitivity to marbofloxacin or
other (fluoro)quinolones or to any of the
excipients.
Do not use in dogs and cats with central nervous system (CNS)
disorders, such as epilepsy, as fluoroquinolones could
potentially cause seizures in predisposed animals
Do not use in dogs aged less than 12 months or less than 18 months for
exceptionally large breeds of dogs,
such as
Great
Danes,
Briard,
Bernese,
Bouvier and Mastiffs,
with a longer growth period as the fluoroquinolones have been
shown to induce erosion of the articular cartilage in juvenile dogs.
Not recommended for use in cats aged less than 16
weeks.
I
R
I
S
H
M
E
D
I
C
I
N
E
S
B
O
A
R
D
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___

                                
                                Lugege kogu dokumenti